A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
Newsflash:
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
EDITOR’S PICKS
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
Recent clinical developments offer hope for immunosuppression-free diabetes treatment while raising serious questions about safety in gene therapy for muscular …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory vaccines.
Longstanding trend of mega-rounds continues as February sees billions channeled into companies advancing therapies for oncology, rare diseases, and next-gen discovery platforms.
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing cell implant study.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?